Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea

Blockhead09-24

Regeneron stock toppled Monday after a West Virginia judge unexpectedly rejected a preliminary injunction that would have prevented Amgen (AMGN) from launching a biosimilar copycat of eye drug Eylea. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2469178868?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2020/08/Stock-regeneron-01-shutt-150x150.jpg","is_english":true,"pubTime":"2024-09-24 04:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2469178868","market":"sg","top_or_hot":-1,"title":"Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea","media":"Blockhead","content":"<div>\n<p>Regeneron stock toppled Monday after a West Virginia judge unexpectedly rejected a preliminary injunction that would have prevented Amgen (AMGN) from launching a biosimilar copycat of eye drug Eylea.\n...</p>\n\n<a href=\"https://www.investors.com/news/technology/regeneron-stock-amgen-eylea-biosimilar/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-24 04:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/regeneron-stock-amgen-eylea-biosimilar/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron stock toppled Monday after a West Virginia judge unexpectedly rejected a preliminary injunction that would have prevented Amgen (AMGN) from launching a biosimilar copycat of eye drug Eylea.\n...</p>\n\n<a href=\"https://www.investors.com/news/technology/regeneron-stock-amgen-eylea-biosimilar/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0114720955.EUR","symbol_name":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","start_time":0,"source_url":"https://www.investors.com/news/technology/regeneron-stock-amgen-eylea-biosimilar/","article_id":"2469178868","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2020/08/Stock-regeneron-01-shutt-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2469178868","pubTimestamp":1727122419,"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Regeneron stock toppled Monday after a judge unexpectedly rejected a request that would have prevented Amgen from launching an Eylea copycat.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","REGN":"再生元制药公司","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0058720904.USD":"联博国际健康护理基金A","BK4007":"制药","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4566":"资本集团","BAYRY":"Bayer A.G.","LU0882574055.USD":"富达全球健康医疗A ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4588":"碎股","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","AMGN":"安进","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","BK4581":"高盛持仓","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC"},"translate_title":"安进(Amgen)将其竞争对手推向赚钱机器Eylea，再生元(Regeneron)股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":1,"AMGN":1,"REGN":1},"content_text":"Regeneron stock toppled Monday after a West Virginia judge unexpectedly rejected a preliminary injunction that would have prevented Amgen (AMGN) from launching a biosimilar copycat of eye drug Eylea.\n\n\n\n↑\nX\n\n\n\n\nBiotech Stocks Are Shooting Higher. Here's How You Can Play Them.\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nBiotech Stocks Are Shooting Higher. Here's How You Can Play Them.\n\n\n\n\nThe move means Amgen could launch its knockoff of the eye disease treatment at risk while the companies are battling it out in court, RBC Capital Markets analyst Brian Abrahams said in a client note. The Food and Drug Administration signed off on Amgen's version of Eylea, dubbed Pavblu, last week.\nEylea is one of Regeneron Pharmaceuticals' (REGN) biggest drugs. In 2023, it brought in $9.38 billion in worldwide sales. Regeneron records U.S. sales and Bayer (BAYRY) records international sales.\n\"It is yet unclear whether Amgen will launch Pavblu at risk, as Amgen would be subject to treble damages\" if Regeneron appeals and wins, RBC's Abrahams said. He added that, \"We note Amgen has launched their biosimilar products at risk in the past.\"\nRegeneron stock tumbled 4.6%, closing at 1,091.98. Amgen stock also dipped a fraction to 335.61.\nRegeneron Stock: Appeal Expected\nAn Amgen spokesperson said the company is planning to announce its launch timing \"in due course.\"\n\"We are pleased with the court's decision denying Regeneron's request for a preliminary injunction,\" she said in an email to Investor's Business Daily. \"Our biosimilar product, Pavblu, does not infringe Regeneron's patent.\"\nBut Regeneron is planning to appeal the decision from the Northern District Court of West Virginia. A company spokesperson noted the decision only applies to Amgen, not other makers of biosimilar copies of Eylea.\nImportantly, the decision only applies to the standard dose of Eylea. Regeneron also sells a high-dose version of Eylea. This version requires less frequent dosing. Eylea HD sales are small, but ramping. Last year, the high-dose version brought in $165.8 million in sales.\n\"Regeneron has invested many years of effort into its design and development of Eylea,\" the company said in a written statement. \"This work has resulted in numerous patents, reflecting our important research and innovation. We continue to believe that Amgen is infringing our patent rights, and today's decision denying our request for a preliminary injunction is not the final word in this litigation.\"\nIRA Will Play A Role\nRBC's Abrahams says the court battle could have important implications for Eylea when it comes to Medicare negotiations. Under the Inflation Reduction Act, the Centers for Medicare and Medicaid Services are already negotiating the prices of a handful of high-cost drugs. Eylea, if it isn't facing lower-cost biosimilars, could soon be targeted for a lower, negotiated price.\n\"The appeals decision is unlikely to come before early 2026 — a timeline at which we believe biosimilars will need to be on the market for both Eylea and Eylea HD to avoid IRA pricing negotiation,\" he said.\nHe sees the news as \"incrementally negative to Regeneron's story,\" but kept his outperform rating on Regeneron stock.\n\"The Eylea franchise has not been core to our bullish thesis — we already assume biosimilar (Eylea) launch in early 2026 at the latest and meaningful erosion to Eylea/Eylea HD in out-year sales,\" he said. He estimates U.S. sales stabilizing at about $3.8 billion annually in later years.\nFollow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.\nYOU MAY ALSO LIKE:\nBiohaven Surges After Delaying Progression By Up To 70% In A Rare Disease\nAstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug\nLooking For The Next Big Stock Market Winners? Start With These 3 Steps\nShort-Term Trades Can Add Up To Big Profits. IBD's SwingTrader Shows You How.\nFind Today's Best Growth Stocks To Watch With IBD 50","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2469178868"}